This case displays limited utility of left ventricular ejection fraction to detect acute graft failure due to microvascular vasculopathy and suspected humoral rejection. Despite severe and progressive graft failure, clinically and by right heart catheterizations, left ventricular ejection fraction remained unchanged, indicating need of more reliable noninvasive methods for graft function surveillance. Global longitudinal strain relates to clinical heart failure, filling pressure, and cardiac index during suspected humoral rejection and microvascular dysfunction in this HTX patient. We suggest routine monitoring of graft function by global longitudinal strain as supplement to routine left ventricular ejection fraction and diastolic Doppler measurements.
Introduction
Heart transplant recipients are at increased risk to develop myocardial dysfunction due to rejections, fibroses, and vasculopathy. Standard surveillance of graft function after heart transplantation (HTX) includes measurement of left ventricular (LV) ejection fraction (EF) and diastolic function by mitral valve Doppler flow. Our clinical experience shows that left LV-EF often presents itself within normal range during acute rejection, despite severe vasculopathy, suggesting that LV-EF is an inappropriate parameter for detecting impaired myocardial function. Global longitudinal strain (GLS) by 2-dimensional speckle tracking (2D-STE) represents a new angle-independent echocardiographic tool for global assessment of LV systolic function. GLS is a direct measurement of myocardial longitudinal deformation, less dependent on heart rate and loading conditions than LV-EF and diastolic Doppler measurements [1] . This case displays limited utility of LV-EF to detect acute graft failure due to microvascular vasculopathy and suspected humoral rejection. On the contrary, GLS related to clinical heart failure, filling pressure, and cardiac index during the clinical course.
Case Presentation
A 49-year-old female heart-transplanted (HTX) patient was hospitalized on December 3, 2010, due to one week with dyspnea (NYHA IIb) and dizziness. Blood pressure was 143/100, heart rate 125 (sinus rhythm (SR)), and saturation 97%. Nt-Pro-BNP was moderately elevated, 2018 ng/L. Chest X-ray was without acute pathology. The patient was priorly transplanted in March 2008 due to terminal ischemic heart failure. Donor was an 18-yearold male; both donor and patient were blood type A. Transplantation was completed with 4 HLA mismatches (HLA-A30; B7; DRB1 * 07, * 12). No prospective cytotoxic crossmatch was performed. Cold ischemic time was three hours; the heart started spontaneously in SR. Echocardiography showed normal biventricular systolic function. First endomyocardial biopsy (EMB) showed signs of ischemic transport damage, afterwards no treatment demanding rejections. Coronary angiographies showed normal coronary arteries within the first two years after HTX.
Echocardiography at hospitalization (December 2010) revealed significant restrictive filling with preserved LV-EF but decreased longitudinal biventricular function (EF 55%, E/A-ratio 2.4, E-deceleration time 60 ms, IVRT 46 ms, LVglobal longitudinal strain (GLS) −8.9%, TAPSE 1 cm, and right ventricular (RV)-GLS −6.4%). Intravenous methylprednisolone of 1 g daily for three days was immediately initiated, due to severe suspected acute cellular rejection. EMB and coronary angiography on December 6 showed 1R cellular rejection, significant myocytolysis, and angiographically normal coronary arteries. Intravascular ultrasound examination of all three major branches on December 13 confirmed normal coronary arteries, and repeated EMB showed 1R cellular rejection with significant myocytolysis. C4d was only positive in necrotic areas; no significant histological signs of humoral rejection were described. A DDD-pacemaker was implanted due to symptomatic episodes with sinus bradycardia and nodal rhythm. On December 16 a flow cytometric crossmatch performed on donor T-and Bcells was found negative, not supporting the diagnosis of humoral rejection. Luminex analysis showed three donorspecific HLA antibodies, anti-DR12 (5.200 MFI), anti-DR7 (2.500 MFI), and anti-DR52 (3.500 MFI) indicating some donor reactivity. Serological markers of myocardial necrosis remained elevated. The clinical condition declined with decreasing diuresis, increasing s-creatinine, and dyspnea (NYHA IV). Right heart catheterization on December 28 showed severely elevated biventricular filling pressure and heart failure (right atrium (RA) 23/14 mmHg (20), pulmonary artery (PA) 32/20 mmHg (24), pulmonary capillary wedge pressure (PCWP) 27/10 mmHg (18), and cardiac index (CI) 1.7 L/min, SvO2 53% SaO2 92%). At this point Nt-Pro-BNP was increased to 5034 ng/L. Former EMBs were reevaluated revealing occlusion of several minor arterial branches. Overall, humoral rejection was most likely the cause of microvascular dysfunction. On December 29, plasmaferese, intravenous methylprednisolone, immunoglobulin, and rituximab were initiated. Echocardiography showed unchanged preserved LV-EF and severely reduced biventricular longitudinal function (LV-EF 49%, LV-GLS: −8.6%, TAPSE: 0.8 cm, cm/s, RV-GLS: −6.1%) (Figure 1 (22), PCWP: 22/13 mmHg (17), CI: 1.1 L/min, and SvO2: 36-37%). LV-EF was still near normal, but longitudinal function of both ventricles was further decreasing (LV-EF: 49%, LV-GLS: −5.4%, TAPSE: 0.3 cm, and RV-GLS: −3.4%) (Figure 2) . Levosimendan was added to the treatment. On January 7 the patient developed cardiac arrest and was successfully resuscitated and cardiopulmonary support was initiated. The patient was listed for re-HTX as urgent call. Successful re-HTX was performed on January 11.
Autopsy findings of the explanted heart revealed histological signs of humoral rejection with severe graft vasculopathy in the microvascular system by means of occlusive intima fibrosis involving myofibroblast proliferation, macrophages, and lymphocytes. In the myocardium, severe diffuse myocytolysis and bleeding were seen (Figure 2) . No signs of infection, significant cellular rejection, or epicardial vasculopathy were seen. Mixed beads analysis from 20.06.2011 was negative with no sign of MIC-A antibodies.
Discussion
The diagnostics of humoral rejection and microvascular dysfunction are challenging in the clinical setting. Despite relevant examinations, treatment for humoral rejection in this present case was initiated 26 days after hospitalizing. Microvascular dysfunction and humoral rejection should be suspected in HTX patients with clinical heart failure, without evidence of cellular rejection or epicardial vasculopathy. The combination of preserved LV-EF and severely reduced GLS indicates impaired subendocardial perfusion. Longitudinal myocardial function predominantly represents function of the subendocardial longitudinally oriented fibers. These fibers are the most sensitive for impaired myocardial perfusion, edema, and fibrosis [2] . GLS by 2D-speckle tracking is a direct global angle independent measure of myocardial longitudinal deformation, less dependent on heart rate and loading conditions than EF and diastolic Doppler measurements [1] . Previous studies have shown significantly reduced GLS in stabile HTX patients as compared to healthy subjects [3, 4] and an important prognostic marker within the first two years after HTX [5, 6] . However, the correlation between GLS and microvascular dysfunction in HTX patients remains to be determined.
In this case, progressive heart failure was confirmed by elevated filling pressures, decreased CI, and long-axis analysis of both ventricles, whereas LV-EF was only slightly affected and unchanged during the clinical course. When evaluating myocardial function in HTX patients, LV-EF is often within normal range despite significant cardiac rejection or vasculopathy, indicating that LV-EF is unreliable in graft function surveillance.
Conclusion
In contrast to LV-EF, GLS relates to clinical heart failure, filling pressure, and CI during microvascular dysfunction and suspected humoral rejection in HTX patients. We suggest routine monitoring of graft function by GLS as supplement to routine LV-EF and diastolic Doppler measurements.
